Cargando…

Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies

Background: Androgen deprivation therapy (ADT) suppresses the production of androgen, and ADT is broadly used for intermediate or higher risk disease including advanced and metastatic cancer. ADT is associated with numerous adverse effects derived from the pharmacological properties. Previous meta-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Cheng Chih, Chen, Po Yen, Wang, Shih Wei, Tsai, Meng Hsuan, Wang, Yu Chin Lily, Tai, Ching Ling, Luo, Hao Lun, Wang, Hung-Jen, Chen, Chung Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378175/ https://www.ncbi.nlm.nih.gov/pubmed/34421586 http://dx.doi.org/10.3389/fphar.2021.652979

Ejemplares similares

First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
por: Wu, Szu-Yuan, et al.
Publicado: (2020)

Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes
por: Lazzerini, Pietro Enea, et al.
Publicado: (2020)

A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer
por: Tsai, Chin-Hsien, et al.
Publicado: (2017)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma
por: Lee, Chi-Ho, et al.
Publicado: (2017)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study
por: Chen, Wei-Cheng, et al.
Publicado: (2023)

The Impact of Exercise on Improving Body Composition and PSA in High-Risk Prostate Cancer Patients on Androgen-Deprivation Therapy
por: Lin, Yu-Ching, et al.
Publicado: (2022)

Medication utilization evaluation of androgen deprivation therapy for prostate cancer in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2020)

Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials
por: Zhuang, Junlong, et al.
Publicado: (2023)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
por: Li, Jian-Ri, et al.
Publicado: (2017)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer
por: van Oostwaard, Marsha M., et al.
Publicado: (2022)

The Effects of Statins on Prostate Cancer Patients Receiving Androgen Deprivation Therapy or Definitive Therapy: A Systematic Review and Meta-Analysis
por: Hou, Yu-Chen, et al.
Publicado: (2022)

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation
por: Hou, Wei-Hsien, et al.
Publicado: (2017)

Salvage Radiotherapy Plus Androgen Deprivation Therapy for High-Risk Prostate Cancer with Biochemical Failure after High-Intensity Focused Ultrasound as Primary Treatment
por: Huang, Ying-Che, et al.
Publicado: (2022)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
por: Qin, Caipeng, et al.
Publicado: (2022)

Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling Pathway
por: Tung, Yu-Tang, et al.
Publicado: (2022)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
por: Lu, Yu-Cheng, et al.
Publicado: (2022)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2019)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
por: Neubecker, Katherine, et al.
Publicado: (2011)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation
por: Wu, Chun-Te, et al.
Publicado: (2018)

Simvastatin Sensitizes Radioresistant Prostate Cancer Cells by Compromising DNA Double-Strand Break Repair
por: Chen, Yu-An, et al.
Publicado: (2018)

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
por: Zhong, Shangwei, et al.
Publicado: (2022)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

The clinical guiding value of a radiomics model for androgen deprivation therapy for prostate cancer
por: Yu, Na, et al.
Publicado: (2021)

Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study
por: Li, Jian-Ri, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pm4ifvkf717mssfk101ten3b0s